Cross‐Cultural Adaptation and Psychometric Assessment of the CULIG's Questionnaire to Measure the Extent and Reasons for Medication Nonadherence in Iranian Patients With Type 2 Diabetes During (2017–2018): A Cross‐Sectional Study

Read full text
Authors: Susan Arghadeh, Hassan Mahmoodi, Seemin Dashti, Parvin Sarbakhsh, Abdolreza Shaghaghi
Cited by: 0
References: 23

Abstract

Background and Aims: This study aimed to test adaptability of the CULIG's questionnaire (CULIG-P) for assessment of medication regimen adherence among the Persian speaking patients with type 2 diabetes. Methods: A standard forward and backward translation procedure was utilized to adapt first draft of the CULIG-P which was sent in the next stage to 15 experts for content and face validities' appraisal. The approved final draft of the CULIG-P was completed by the 304 recruited patients with type 2 diabetes. Cronbach's alpha and Kappa with Linear weighting were also estimated to check internal consistency and reliability of the scale. The structural validity of the CULIG-P was examined using exploratory factor analysis (EFA). Results: The values of Cronbach's alpha (0.77) and weighted kappa coefficient for most of the scale's items were in acceptable range. Content Validity Index (CVI) and Content Validity Ratio (CVR) were also indicated reasonable construct of the CULIG-P for assessment of the reasons of medication regimen nonadherence among the study participants. The implemented factor analysis with varimax rotation extracted five factors which explained 41.81% of the data's total variance. Conclusions: The findings revealed usability of the CULIG-P in studies and probably practice settings for assessment of medication regimen adherence/nonadherence in Persian-speaking type 2 diabetes patients.

Fields of Study & Subjects

Medication Adherence and Compliance Diabetes Management and Education Health Education and Validation

Publication details

Journal / source
Health Science Reports
Volume
9
Issue
3
Pages
e71893–e71893
Publication date
28 February 2026
Language
EN